CLINICAL TRIALS PROFILE FOR XEOMIN
✉ Email this page to a colleague
All Clinical Trials for XEOMIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00406367 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-10-01 | Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period. |
| NCT00407030 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-07-01 | At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period. |
| NCT00430963 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-10-01 | IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each. |
| NCT00432666 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-06-01 | IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb. |
| NCT00465738 ↗ | IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2007-02-01 | This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin). |
| NCT00512135 ↗ | Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2007-06-18 | The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study. |
| NCT00515944 ↗ | Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products | Completed | Merz Pharmaceuticals GmbH | Phase 1 | 2007-08-01 | Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XEOMIN
Condition Name
Clinical Trial Locations for XEOMIN
Trials by Country
Clinical Trial Progress for XEOMIN
Clinical Trial Phase
Clinical Trial Sponsors for XEOMIN
Sponsor Name
